Compare · ANRO vs NVO
ANRO vs NVO
Side-by-side comparison of Alto Neuroscience Inc. (ANRO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANRO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.10B, about 264.0x ANRO ($742.9M).
- Over the past year, ANRO is up 809.9% and NVO is down 43.0% - ANRO leads by 852.9 points.
- ANRO has been more active in the news (5 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 13 for ANRO).
- Company
- Alto Neuroscience Inc.
- Novo Nordisk A/S
- Price
- $21.11-2.63%
- $43.91+0.06%
- Market cap
- $742.9M
- $196.10B
- 1M return
- -10.47%
- -4.14%
- 1Y return
- +809.91%
- -43.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 4
- Recent ratings
- 13
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANRO
- Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
- SEC Form 4 filed by Director Miller Andrew Craig
- SEC Form 3 filed by new insider Miller Andrew Craig
- Alto Neuroscience Inc. filed SEC Form 8-K: Leadership Update
- Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
- Wolfe Research initiated coverage on Alto Neuroscience
- PRESIDENT AND CEO Etkin Amit gifted 400,000 shares, decreasing direct ownership by 32% to 833,949 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Alto Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Alto Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Alto Neuroscience Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S